The objective of our retrospective study was to confirm KRAS/NRAS (RAS) and BRAF mutation rates in a Turkish cohort of 694 patients diagnosed with CRC using next-generation sequencing (NGS). The gene discussed is KRAS; the disease is colorectal carcinoma.